What does 21 CFR Part 11 require for electronic signatures in batch record review?
By Savi C., Co-Founder · Published Nov 16, 2026
When the signature rules apply
Part 11 defines an electronic signature as a computer data compilation of any symbol or series of symbols executed, adopted or authorized by an individual to be the legally binding equivalent of that individual’s handwritten signature. Whenever a batch record that CGMP requires is signed in a computer system, by the operator, the checker, the production reviewer or the QA approver, these rules apply.
FDA’s December 2018 data integrity guidance confirms that electronic signatures with appropriate controls can be used in place of handwritten signatures or initials in any CGMP record. That includes the full handwritten signature 211.186(a) specifies for master production and control records, provided the controls securely link the signature to the record. FDA also asks firms to document the controls that let them identify the specific person who signed.
The signature sections, applied to batch review
Section
11.50(a)
What it means for review and release
Each signed record shows the signer’s printed name, the date and time of signing, and the meaning, such as review, approval, responsibility or authorship
Section
11.50(b)
What it means for review and release
Those three items are controlled like the record itself and appear on every human readable form, including screens and printouts used in review
Section
11.70
What it means for review and release
Electronic signatures, and handwritten signatures executed to electronic records, are linked to their records so they cannot be excised, copied or otherwise transferred to falsify a record by ordinary means
Section
11.100(a) and (b)
What it means for review and release
Each signature belongs to one person, is never reused or reassigned, and is issued only after the organisation has verified that person’s identity
Section
11.100(c)
What it means for review and release
The organisation certifies to FDA, with a handwritten signature, that its electronic signatures are the legally binding equivalent of handwritten ones
Section
11.200(a)
What it means for review and release
At least two components, such as ID and password, used only by their genuine owners, with misuse requiring collaboration of two or more people
Section
11.200(b)
What it means for review and release
Biometric signatures are designed so no one but their owner can use them
Section
11.300
What it means for review and release
Unique ID and password combinations, periodic checks or revision, loss management for tokens and cards, transaction safeguards and device testing
Section
11.10(g) and (j)
What it means for review and release
Authority checks so only authorised people can sign, and written policies holding individuals accountable for actions under their signatures
What a reviewer should be able to confirm
On each signed entry
- Printed name, date, time and meaning are all visible, not only a user ID
- The meaning matches the role: performed, verified, reviewed or approved
- The signer was authorised for that step on that date, according to the training and access records
- No data in the signed section changed after signing, or the signature shows as invalidated and re-applied
On the system
- The signature workflow was validated, including what happens when signed data is edited
- Signatures cannot be applied by someone logged in under another person’s session
- A signing outside a continuous session asks for every component, not a password alone
- Printouts and PDF exports carry the signature manifestation and its metadata
On people
- No shared or generic accounts exist for anyone who signs batch records
- Leavers and role changes are removed from signing rights promptly
- The site’s certification letter to FDA under 11.100(c) is on file
Hybrid records and printed copies
Many sites sign electronically in some systems and on paper in others. Section 11.70 covers both directions: a handwritten signature executed to an electronic record has to be linked to that record just as firmly as an electronic one. A signed paper printout that floats free of the electronic data it summarises does not meet that test.
Two guidance points are worth building into review. PIC/S PI 041-1 says that if a signed record is later changed, the record should show the amendment and appear as unsigned until it is reviewed and signed again. The MHRA says an inserted image of a signature, or a footnote saying a document was signed, is not adequate unless it came from the validated signature process, and that the signature metadata should stay with any paper or PDF copy.
How Litewave fits
Litewave supports 21 CFR Part 11 electronic records, signatures and audit trails. It reads paper or electronic records, checks every entry against your master record and specifications, including whether each required signature is present, in sequence and from an authorised role, and shows QA only the exceptions, each linked to the page it came from. Litewave proposes, qualified people approve, and the release signature is always applied by your qualified person.
Questions we get asked
Can a reviewer sign a series of records with just a password?
Within limits. Under 11.200(a)(1)(i), during a single, continuous period of controlled system access, the first signing uses all components and later signings need at least one component that only that individual can execute. Any signing outside such a session needs every component.
Does the signature have to show the signer’s job title?
Part 11 does not require it. Section 11.50 requires the printed name, the date and time, and the meaning of the signature. The MHRA’s guidance does mention the signer’s title in its description of signature manifestations, so sites supplying the UK often include it.
Do we have to tell FDA we use electronic signatures?
Yes. Section 11.100(c) requires a certification, signed by hand and submitted in electronic or paper form, that your electronic signatures are intended to be the legally binding equivalent of handwritten signatures. FDA’s web page on Letters of Non-Repudiation Agreement explains where to send it.
Sources
- 21 CFR 11.3, Definitions (eCFR)
- 21 CFR 11.10, Controls for closed systems (eCFR)
- 21 CFR 11.50, Signature manifestations (eCFR)
- 21 CFR 11.70, Signature/record linking (eCFR)
- 21 CFR 11.100, General requirements for electronic signatures (eCFR)
- 21 CFR 11.200, Electronic signature components and controls (eCFR)
- 21 CFR 11.300, Controls for identification codes/passwords (eCFR)
- 21 CFR 211.186, Master production and control records (eCFR)
- FDA, Data Integrity and Compliance With Drug CGMP: Questions and Answers (December 2018)
- PIC/S PI 041-1, Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (2021)
- MHRA, GXP Data Integrity Guidance and Definitions, Revision 1 (March 2018)
